Literature DB >> 24266842

Site-restricted plasminogen activation mediated by group A streptococcal streptokinase variants.

Simon M Cook1, Amanda Skora1, Mark J Walker2, Martina L Sanderson-Smith1, Jason D McArthur1.   

Abstract

SK (streptokinase) is a secreted plasminogen activator and virulence factor of GAS (group A Streptococcus). Among GAS isolates, SK gene sequences are polymorphic and are grouped into two sequence clusters (cluster type-1 and cluster type-2) with cluster type-2 being further classified into subclusters (type-2a and type-2b). In the present study, we examined the role of bacterial and host-derived cofactors in SK-mediated plasminogen activation. All SK variants, apart from type-2b, can form an activator complex with Glu-Plg (Glu-plasminogen). Specific ligand-binding-induced conformational changes in Glu-Plg mediated by fibrinogen, PAM (plasminogen-binding group A streptococcal M protein), fibrinogen fragment D or fibrin, were required for type-2b SK to form a functional activator complex with Glu-Plg. In contrast with type-1 and type-2a SK, type-2b SK activator complexes were inhibited by α2-antiplasmin unless bound to fibrin or to the GAS cell-surface via PAM in combination with fibrinogen. Taken together, these data suggest that type-2b SK plasminogen activation may be restricted to specific microenvironments within the host such as fibrin deposits or the bacterial cell surface through the action of α2-antiplasmin. We conclude that phenotypic SK variation functionally underpins a pathogenic mechanism whereby SK variants differentially focus plasminogen activation, leading to specific niche adaption within the host.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24266842     DOI: 10.1042/BJ20131305

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  8 in total

Review 1.  Pathogen activators of plasminogen.

Authors:  I M Verhamme; P R Panizzi; P E Bock
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

2.  In Vivo Tracking of Streptococcal Infections of Subcutaneous Origin in a Murine Model.

Authors:  Richard W Davis; Heather Eggleston; Frances Johnson; Matthias Nahrendorf; Paul E Bock; Tiffany Peterson; Peter Panizzi
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

Review 3.  Tissue tropisms in group A Streptococcus: what virulence factors distinguish pharyngitis from impetigo strains?

Authors:  Debra E Bessen
Journal:  Curr Opin Infect Dis       Date:  2016-06       Impact factor: 4.915

4.  Rapid binding of plasminogen to streptokinase in a catalytic complex reveals a three-step mechanism.

Authors:  Ingrid M Verhamme; Paul E Bock
Journal:  J Biol Chem       Date:  2014-08-19       Impact factor: 5.157

5.  Plasminogen activation by staphylokinase enhances local spreading of S. aureus in skin infections.

Authors:  Marijke Peetermans; Thomas Vanassche; Laurens Liesenborghs; Jorien Claes; Greetje Vande Velde; Jakub Kwiecinksi; Tao Jin; Bart De Geest; Marc F Hoylaerts; Roger H Lijnen; Peter Verhamme
Journal:  BMC Microbiol       Date:  2014-12-17       Impact factor: 3.605

6.  Activity Regulation by Fibrinogen and Fibrin of Streptokinase from Streptococcus Pyogenes.

Authors:  Sian Huish; Craig Thelwell; Colin Longstaff
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

7.  Linoleic and palmitoleic acid block streptokinase-mediated plasminogen activation and reduce severity of invasive group A streptococcal infection.

Authors:  Katharina Rox; Rolf Jansen; Torsten G Loof; Christine M Gillen; Steffen Bernecker; Mark J Walker; Gursharan Singh Chhatwal; Rolf Müller
Journal:  Sci Rep       Date:  2017-09-18       Impact factor: 4.379

8.  Immunoglobulin Attenuates Streptokinase-Mediated Virulence in Streptococcus dysgalactiae Subspecies equisimilis Necrotizing Fasciitis.

Authors:  Federica Andreoni; Fabio Ugolini; Nadia Keller; Andrina Neff; Victor Nizet; Andrew Hollands; Ewerton Marques Maggio; Annelies S Zinkernagel; Reto A Schuepbach
Journal:  J Infect Dis       Date:  2018-01-04       Impact factor: 5.226

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.